Biomarkers Market Demands, Trends and Business Outlook 2028

Biomarkers Industry Overview

The global biomarkers market size was valued at USD 51.18 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 14.2% from 2021 to 2028.

The increasing prevalence of chronic diseases, advancements in the techniques used for the development of biomarker-based diagnostics, and the growing geriatric population are the key factors projected to boost the market growth over the forecast period. The rising number of COVID-19 cases across the globe and an increasing number of researches on the use of biomarkers for facilitating the detection & treatment of COVID-19 will also support market growth.

Gather more insights about the market drivers, restrains and growth of the Global Biomarkers Market

Recent advancements in biomarkers, such as biomarker signatures, are making neurological diseases more treatable. This has resulted in non-invasive testing, faster drug development, and early diagnosis. R&D is leading to the discovery of novel biomarkers. For instance, as per Nature Journal in 2020, tetranectin is a potential biomarker for heart failure diagnosis. Similarly, in 2020, sTNFR2 was revealed as a novel biomarker for the diagnosis of acute adult T-cell leukemia/lymphoma. The market is likely to witness lucrative growth over the forecast period due to such discoveries and technological advancements.

The use of biomarkers in infectious disease diagnosis is anticipated to become increasingly common in the coming years. For instance, as per Frontiers in Microbiology in 2020, potential MicroRNA-based biomarkers have been identified for the diagnosis of infections, such as influenza infections, rhinoviruses, HIV, tuberculosis, malaria, Ebola, and Hendra virus. These miRNA-based biomarkers are aimed at facilitating the early onset of infectious diseases.

Moreover, Amgen announced the launch of the Biomarker Assist program in April 2021 to improve access to advanced biomarker testing for non-small cell lung cancer patients. Such programs are anticipated to escalate the adoption rate of novel biomarker tests, thereby facilitating correct and on-time treatment.

A rise in the prevalence of fatal diseases has been observed over the past few years, which includes cancer, diabetes, Cardiovascular Disorders (CVDs), and other chronic diseases. One of the major factors leading to a rise in their prevalence is lifestyle changes. As per the WHO in 2019, ischemic heart disease and stroke have become the leading cause of death globally, accounting for around 8.9 million deaths globally followed by stroke and COPD.

Browse through Grand View Research’s Clinical Diagnostics Industry Research Reports.

• Point Of Care Diagnostics Market: The global point of care diagnostics market size was valued at USD 37.03 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.8% from 2022 to 2030.
• Blood Transfusion Diagnostics Market: The global blood transfusion diagnostics market size was valued at USD 3,713.7 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.6% from 2021 to 2027. 

Market Share Insights

• March 2021: A novel biomarker-based non-diagnostic screening device was approved by the U.S. FDA called Tiger Tech COVID plus Monitor.
• January 2020: Biocept, Inc. launched the Target Selector platform and assays that allow physicians to evaluate circulating tumor cells and breast/lung cancer-associated biomarkers in the CSF of patients.

Key Companies profiled:

Some prominent players in the global biomarkers market include:

• Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Epigenetics AG
• General Electric
• Johnson & Johnson Services, Inc.
• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories, Inc.
• Siemens Healthineers AG
• Qiagen

Order a free sample PDF of the Biomarkers Market Intelligence Study, published by Grand View Research.